浆细胞肿瘤的骨髓免疫组织学
Bone marrow immunohistology of plasma cell neoplasms.
作者信息
Wei A, Juneja S
机构信息
Department of Haematology, The Royal Melbourne Hospital, Parkville, 3050, Victoria, Australia.
出版信息
J Clin Pathol. 2003 Jun;56(6):406-11. doi: 10.1136/jcp.56.6.406.
Abstract
The application of immunohistology to the spectrum of plasma cell disorders has yet to be incorporated widely into routine haematology practice. This technique enables the direct visualisation of specific surface and cytoplasmic antigens in the context of the individual cell and the surrounding anatomical neighbourhood. This review outlines the role of bone marrow immunohistology in the laboratory evaluation of patients with suspected and established plasma cell neoplasms and its emerging role in understanding myeloma biology for possible future therapeutic application.
摘要
免疫组织学在浆细胞疾病谱中的应用尚未广泛纳入常规血液学实践。这项技术能够在单个细胞及其周围解剖结构的背景下直接可视化特定的表面和细胞质抗原。本综述概述了骨髓免疫组织学在疑似和确诊浆细胞肿瘤患者实验室评估中的作用，以及其在理解骨髓瘤生物学以用于未来可能的治疗应用方面的新作用。
相似文献
1
Bone marrow immunohistology of plasma cell neoplasms.
J Clin Pathol. 2003 Jun;56(6):406-11. doi: 10.1136/jcp.56.6.406.
2
3
[Laboratory diagnosis of myeloma disease (review of the literature)].
Vrach Delo. 1982 Jan(1):57-61.
4
Diagnosis and management of multiple myeloma and related disorders.
Prog Hematol. 1986;14:257-82.
5
Plasma cell neoplasms and related entities-evolution in diagnosis and classification.
Virchows Arch. 2023 Jan;482(1):163-177. doi: 10.1007/s00428-022-03431-3. Epub 2022 Nov 21.
6
Benign and malignant monoclonal gammopathies.
Prim Care. 1980 Sep;7(3):369-94.
7
Serum free light chains in the diagnosis and monitoring of patients with plasma cell dyscrasias.
Contrib Nephrol. 2007;153:44-65. doi: 10.1159/000096760.
8
Plasma cell dyscrasias and amyloidosis.
Otolaryngol Clin North Am. 2003 Aug;36(4):747-64. doi: 10.1016/s0030-6665(03)00026-4.
9
Serum-free light-chain analysis in diagnosis and management of multiple myeloma and related conditions.
Scand J Clin Lab Invest Suppl. 2016;245:S113-8. doi: 10.1080/00365513.2016.1210337. Epub 2016 Jul 28.
10
Bone-marrow plasmocytosis--an immunohistological study.
Blut. 1986 Jul;53(1):11-9. doi: 10.1007/BF00320578.
引用本文的文献
1
Analysis of Normal Plasma Cell Distribution Across Distinct Age Cohorts Reveals Age-Dependent Changes.
J Histochem Cytochem. 2024 Jul;72(7):435-451. doi: 10.1369/00221554241266005. Epub 2024 Jul 25.
2
Cholestatic HCV Cryoglobulinemia: A New Clinical and Pathological Entity before and after Direct-Acting Antiviral Therapies-A Case-Control Study.
Int J Mol Sci. 2024 Jan 8;25(2):784. doi: 10.3390/ijms25020784.
3
Gastrointestinal bleeding as initial presentation of extramedullary plasma cell neoplasms: A case report and review of the literature.
World J Gastrointest Endosc. 2019 Apr 16;11(4):308-321. doi: 10.4253/wjge.v11.i4.308.
4
Role of CD138, CD56, and light chain immunohistochemistry in suspected and diagnosed plasma cell myeloma: A prospective study.
South Asian J Cancer. 2019 Jan-Mar;8(1):60-64. doi: 10.4103/sajc.sajc_64_17.
5
Subcutaneous scalp nodule as the presenting symptom of systemic light-chain amyloidosis.
Dermatol Pract Concept. 2018 Jul 31;8(3):184-187. doi: 10.5826/dpc.0803a07. eCollection 2018 Jul.
6
The risk of renal disease is increased in lambda myeloma with bone marrow amyloid deposits.
J Blood Med. 2017 Mar 6;8:29-34. doi: 10.2147/JBM.S129516. eCollection 2017.
7
Solitary Bone Plasmacytoma of the Pelvis: A Rare Tumor.
Rare Tumors. 2016 Apr 6;8(1):6306. doi: 10.4081/rt.2016.6306. eCollection 2016 Mar 21.
8
Imaging Findings and Literature Review of (18)F-FDG PET/CT in Primary Systemic AL Amyloidosis.
Nucl Med Mol Imaging. 2015 Sep;49(3):182-90. doi: 10.1007/s13139-015-0338-0. Epub 2015 May 13.
9
Reticuloendothelial malignancy of head and neck: A comprehensive review.
J Pharm Bioallied Sci. 2015 Apr;7(Suppl 1):S145-57. doi: 10.4103/0975-7406.155867.
10
Variant morphology in multiple myeloma.
Indian J Hematol Blood Transfus. 2014 Sep;30(Suppl 1):86-7. doi: 10.1007/s12288-013-0259-y. Epub 2013 Apr 26.
本文引用的文献
1
Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation.
Blood. 2002 Nov 1;100(9):3095-100. doi: 10.1182/blood-2001-12-0297.
2
3
Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells.
Blood. 2002 Jul 1;100(1):194-9. doi: 10.1182/blood.v100.1.194.
4
Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma.
Br J Haematol. 2002 Jun;117(4):882-5. doi: 10.1046/j.1365-2141.2002.03513.x.
5
Bone marrow angiogenesis and plasma cell angiogenic and invasive potential in patients with active multiple myeloma.
Acta Haematol. 2001;106(4):162-9. doi: 10.1159/000046612.
6
Diagnosis and management of multiple myeloma.
Br J Haematol. 2001 Dec;115(3):522-40. doi: 10.1046/j.1365-2141.2001.03206.x.
7
Multiple myeloma.
Hematology Am Soc Hematol Educ Program. 2001:157-77. doi: 10.1182/asheducation-2001.1.157.
8
Cyclin D1 overexpression in multiple myeloma. A morphologic, immunohistochemical, and in situ hybridization study of 71 paraffin-embedded bone marrow biopsy specimens.
Am J Clin Pathol. 2001 Oct;116(4):535-42. doi: 10.1309/BVT4-YP41-LCV2-5GT0.
9
Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions.
Mod Pathol. 2001 Oct;14(10):1052-8. doi: 10.1038/modpathol.3880435.
10
Waldenström macroglobulinemia. Development of diagnostic criteria and identification of prognostic factors.
Am J Clin Pathol. 2001 Sep;116(3):420-8. doi: 10.1309/4LCN-JMPG-5U71-UWQB.
Zotero 插件